TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06075264: Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)

Sponsor: Frantz Viral Therapeutics, LLC · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 27 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$1,247,400

Rescue Site Savings

+$831,600

Unlock Full NCT06075264 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06075264 Rescue Dossier →